Glaxo Ziagen/Agenerase
Executive Summary
Viral loads of less than five copies/mL were achieved by 48 weeks in 39% of patients (16/41) treated with a combination regimen of Agenerase (amprenavir) and Ziagen (abacavir) and 47% of patients (19/40) by week 72, a Phase II study evaluating early stage HIV-positive individuals treated with the two-drug combination demonstrated. The study presented at ICAAC also observed that the CD4 cell count of 41 Agenerase/Ziagen treated individuals increased from a baseline count of 756 to 878 at week 24. In comparison, HIV-negative patients maintained a count of 967 CD4 cells
Viral loads of less than five copies/mL were achieved by 48 weeks in 39% of patients (16/41) treated with a combination regimen of Agenerase (amprenavir) and Ziagen (abacavir) and 47% of patients (19/40) by week 72, a Phase II study evaluating early stage HIV-positive individuals treated with the two-drug combination demonstrated. The study presented at ICAAC also observed that the CD4 cell count of 41 Agenerase/Ziagen treated individuals increased from a baseline count of 756 to 878 at week 24. In comparison, HIV-negative patients maintained a count of 967 CD4 cells. |